IL236679A0 - Preparations and methods for regulating car t cells - Google Patents

Preparations and methods for regulating car t cells

Info

Publication number
IL236679A0
IL236679A0 IL236679A IL23667915A IL236679A0 IL 236679 A0 IL236679 A0 IL 236679A0 IL 236679 A IL236679 A IL 236679A IL 23667915 A IL23667915 A IL 23667915A IL 236679 A0 IL236679 A0 IL 236679A0
Authority
IL
Israel
Prior art keywords
compositions
cells
methods
regulating car
regulating
Prior art date
Application number
IL236679A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of IL236679A0 publication Critical patent/IL236679A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL236679A 2012-07-13 2015-01-12 Preparations and methods for regulating car t cells IL236679A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261671518P 2012-07-13 2012-07-13
PCT/US2013/050272 WO2014011987A1 (en) 2012-07-13 2013-07-12 Compositions and methods for regulating car t cells

Publications (1)

Publication Number Publication Date
IL236679A0 true IL236679A0 (en) 2015-02-26

Family

ID=49916567

Family Applications (1)

Application Number Title Priority Date Filing Date
IL236679A IL236679A0 (en) 2012-07-13 2015-01-12 Preparations and methods for regulating car t cells

Country Status (14)

Country Link
US (3) US20150140019A1 (enExample)
EP (1) EP2872218A4 (enExample)
JP (1) JP2015525765A (enExample)
KR (1) KR20150030724A (enExample)
CN (1) CN104507537A (enExample)
AU (1) AU2013289970A1 (enExample)
BR (1) BR112015000310A2 (enExample)
CA (1) CA2878856A1 (enExample)
EA (1) EA201590207A1 (enExample)
IL (1) IL236679A0 (enExample)
IN (1) IN2014DN10889A (enExample)
MX (1) MX2015000428A (enExample)
SG (1) SG11201408398UA (enExample)
WO (1) WO2014011987A1 (enExample)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2833918B1 (en) 2012-04-05 2019-05-08 Massachusetts Institute of Technology Immunostimulatory compositions and methods of use thereof
EP3653212B1 (en) 2012-12-20 2023-04-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CA2901960C (en) 2013-02-20 2022-10-04 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
UY35340A (es) 2013-02-20 2014-09-30 Novartis Ag Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
EP3623380B1 (en) 2013-03-15 2025-10-22 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
AU2014366047B2 (en) 2013-12-19 2021-03-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US11452768B2 (en) 2013-12-20 2022-09-27 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
ES2963718T3 (es) 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
HRP20240874T1 (hr) 2014-04-07 2024-10-11 Novartis Ag Liječenje raka korištenjem kimernog antigenskog receptora anti-cd19
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
SG11201700476VA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
CA2955465A1 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
EP3722316A1 (en) 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
EP3967709A1 (en) 2014-09-17 2022-03-16 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US10774388B2 (en) 2014-10-08 2020-09-15 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
JP6898244B2 (ja) * 2014-11-06 2021-07-07 ユニバーシティー オブ メリーランド，ボルティモア ＣＤ８αおよびＴ細胞受容体の変異体ならびに免疫細胞の応答の調節においてそれらを使用する方法
CA2969384A1 (en) * 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
CN107567461A (zh) 2014-12-29 2018-01-09 诺华股份有限公司 制备嵌合抗原受体表达细胞的方法
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
JP2018504145A (ja) 2015-01-26 2018-02-15 セレクティスＣｅｌｌｅｃｔｉｓ 再発性／難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、ｃｄ１２３に結合するキメラ抗原受容体を賦与された、操作されたｔ細胞受容体ノックアウト免疫細胞
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
BR112017021500A2 (pt) 2015-04-08 2018-09-25 Novartis Ag terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19
JP7114457B2 (ja) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
EP3436575A1 (en) 2015-06-18 2019-02-06 The Broad Institute Inc. Novel crispr enzymes and systems
JP6961497B2 (ja) * 2015-06-25 2021-11-05 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
CN109476722A (zh) * 2015-07-21 2019-03-15 诺华股份有限公司 用于改善免疫细胞的功效和扩张的方法
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
WO2017030370A1 (ko) * 2015-08-17 2017-02-23 서울대학교산학협력단 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도
EP3340995A4 (en) * 2015-08-28 2019-04-03 The Trustees Of The University Of Pennsylvania METHOD AND COMPOSITIONS FOR CELLS FOR EXPRESSING A CHIMERIC INTRA-CELLULAR SIGNAL MOLECULE
EP4218777A3 (en) 2015-08-28 2023-08-23 The Trustees of the University of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN116334205A (zh) 2015-09-03 2023-06-27 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
EA201891338A1 (ru) 2015-12-04 2018-12-28 Новартис Аг Композиции и способы для иммуноонкологии
WO2017112741A1 (en) 2015-12-22 2017-06-29 Novartis Ag Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
US12499971B2 (en) 2016-09-28 2025-12-16 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
WO2018073394A1 (en) * 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
US12227578B2 (en) 2016-11-11 2025-02-18 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2018148671A1 (en) 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
EP3589295B1 (en) 2017-02-28 2024-09-11 Endocyte, Inc. Compositions and methods for car t cell therapy
SG11201907434RA (en) 2017-03-22 2019-10-30 Novartis Ag Compositions and methods for immunooncology
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
CN111093691A (zh) 2017-04-03 2020-05-01 内恩疗法公司 蛋白质抗原及其用途
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
US20210293783A1 (en) 2017-04-18 2021-09-23 The General Hospital Corporation Compositions for detecting secretion and methods of use
WO2018209324A2 (en) 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
EP3625342B1 (en) 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
AU2018288814A1 (en) 2017-06-21 2020-02-06 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), compositions and methods thereof
US12144825B2 (en) 2017-06-30 2024-11-19 Cellectis Cellular immunotherapy for repetitive administration
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
AU2018338318B2 (en) 2017-09-21 2022-12-22 Massachusetts Institute Of Technology Systems, methods, and compositions for targeted nucleic acid editing
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
US11732257B2 (en) 2017-10-23 2023-08-22 Massachusetts Institute Of Technology Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
US12491153B2 (en) 2018-01-03 2025-12-09 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US11779602B2 (en) 2018-01-22 2023-10-10 Endocyte, Inc. Methods of use for CAR T cells
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2019241426A1 (en) 2018-06-13 2019-12-19 Novartis Ag Bcma chimeric antigen receptors and uses thereof
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US12460244B2 (en) 2018-08-20 2025-11-04 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease activity and uses thereof
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
PH12021551485A1 (en) 2018-12-21 2022-04-11 Biontech Us Inc Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
EP3941511A2 (en) 2019-03-20 2022-01-26 Massachusetts Institute of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
EP4028064A1 (en) 2019-09-12 2022-07-20 The Broad Institute, Inc. Engineered adeno-associated virus capsids
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
WO2021108613A1 (en) 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
EP4288073A4 (en) * 2021-02-05 2025-03-26 University of Utah Research Foundation Compositions and methods for treating with car cells
CN117677632A (zh) * 2021-07-21 2024-03-08 韩国生命工学研究院 新型嵌合抗原受体和表达该嵌合抗原受体的免疫细胞
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792447A (en) * 1981-07-23 1988-12-20 Board Of Regents, The University Of Texas System Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
AU2001259792B2 (en) * 2000-03-29 2005-12-22 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive T cells
US7514537B2 (en) * 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
PL1711528T3 (pl) * 2003-12-23 2012-11-30 Genentech Inc Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
AU2006287416A1 (en) * 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
JP5727786B2 (ja) * 2007-10-19 2015-06-03 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１９結合性物質およびその使用
DE102010039018B4 (de) * 2010-08-06 2013-02-28 Technische Universität Dresden Anti-La Antikörper und ihre Anwendung zum Immunotargeting
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2651442B1 (en) * 2010-12-14 2020-04-22 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
CA2913052A1 (en) * 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies

Also Published As

Publication number Publication date
AU2013289970A1 (en) 2015-01-22
US20230034117A1 (en) 2023-02-02
EP2872218A1 (en) 2015-05-20
CN104507537A (zh) 2015-04-08
JP2015525765A (ja) 2015-09-07
WO2014011987A1 (en) 2014-01-16
US20190367610A1 (en) 2019-12-05
US20150140019A1 (en) 2015-05-21
EP2872218A4 (en) 2016-07-06
KR20150030724A (ko) 2015-03-20
CA2878856A1 (en) 2014-01-16
BR112015000310A2 (pt) 2017-06-27
IN2014DN10889A (enExample) 2015-09-11
MX2015000428A (es) 2015-03-12
SG11201408398UA (en) 2015-02-27
EA201590207A1 (ru) 2015-05-29

Similar Documents

Publication Publication Date Title
IL236679A0 (en) Preparations and methods for regulating car t cells
ZA201502884B (en) Compositions and methods for modulating cell signaling
SG10201705024PA (en) Methods and compositions for separating or enriching cells
ZA201502880B (en) Compositions and methods for immunotherapy
IL236158A0 (en) Methods and compositions to create biomethane
SG10201610915XA (en) Methods and compositions for natural killer cells
SG11201408356VA (en) Novel biocatalyst compositions and processes for use
SG11201500799YA (en) Hla g-modified cells and methods
IL238726A0 (en) Preparations and methods for increasing energy metabolism
IL238416A0 (en) Preparations and methods for the treatment of diseases caused by protein pathology
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
IL237916A0 (en) Preparations and methods for preparing glycoproteins
ZA201407412B (en) Method and compositions for preventing stem cell disruption and aggregation
IL239484A0 (en) Materials for omitting enterprise-tumor cells
GB201315350D0 (en) Methods and compositions
EP2909309A4 (en) COMPOSITIONS AND METHODS FOR VITAMINOUS FERMENTATES
GB201315347D0 (en) Methods and compositions
GB201220058D0 (en) Cell differentiation
IL239529B (en) Preparations and methods for creating improved and different cells and organisms
GB201222820D0 (en) Woolscouring method and composition
IL239426A0 (en) Methods and compositions of biomarkers
EP2885001A4 (en) NEW CELL COMPOSITIONS AND METHODS
GB201206859D0 (en) Method and composition
EP2827861A4 (en) COMPOSITION AND METHODS FOR CELLULAR MODULATION
ZA201500172B (en) Plant-disease-control composition and plant-disease-control method